Compared to standard first line cytotoxic chemotherapy, EGFR-TKIs have been shown to prolong progression-free survival (PFS) in NSCLC patients with EGFR-activating mutations, such as exon 19 deletions and L858R point mutations1, 2, 3, 4, 5, 6, 7. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.